The reiteration of an Outperform rating by a reputable analyst like Jay Olson can instill confidence in investors and potentially lead to a positive short term impact on Biogen's stock price. The maintained price target of $295 suggests that the analyst sees continued upside potential for the stock, which could influence investor sentiment and trading behavior.